Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IKT-001 in Pulmonary Arterial Hypertension (PAH)
NCT07365332Phase 3Recruiting
- Sponsor
- Inhibikase Therapeutics, Inc.
- Start
- Apr 2026
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of IKT-001 in pulmonary arterial hypertension (PAH), sponsored by Inhibikase Therapeutics, Inc.. Started Apr 2026; status: recruiting.
02
Drugs
IKT-001
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT07365332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07365332.